Familial hypercholesterolaemia: identification and management
KEYWORDS: people, healthcare, disease, therapy, coronary, healthcare professionals, professionals, children, heart disease, coronary heart, heart, concentration, risk, ldl-c, drug

affected first- and second- and, when possible, third-degree biological relatives of people with a genetic diagnosis of FH. [2017] 1.2.2 Healthcare professionals should offer all people with FH a referral to a specialist with expertise in FH for confirmation of diagnosis and initiation of cascade testing. [2008] 1.2.3 Healthcare professionals with expertise in FH should explain what is meant by cascade testing, and discuss its implications with all people with FH. [2008] 1.2.4 Healthcare professionals should be aware of the latest guidance on data protection when undertaking cascade testing. [2008] 1.3 Management 1.3.1 Drug treatment Adults Recommendations 1.3.1.4 to 1.3.1.9 have been adapted from NICE's technology appraisal guidance on ezetimibe for treating primary (heterozygous-familial and non- familial) hypercholesterolaemia. 1.3.1.1 When offering lipid-modifying drug therapy to adults with FH, healthcare professionals should inform the person that this treatment should be lifelong. [2008]. 1.3.1.2 Offer a high-intensity statin with the lowest acquisition cost as the initial treatment for all adults with FH and aim for at least a 50% reduction in LDL-C concentration from the baseline measurement. [2017] 1.3.1.3 The dose of statin should be increased to the maximum licensed or tolerated dose to achieve a recommended reduction in LDL-C concentration of
